Aimaz Afrough
A5008366988- Multiple Myeloma Research and Treatments
- CAR-T cell therapy research
- Protein Degradation and Inhibitors
- Acute Myeloid Leukemia Research
- Lymphoma Diagnosis and Treatment
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Biosimilars and Bioanalytical Methods
- Chronic Lymphocytic Leukemia Research
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Hematopoietic Stem Cell Transplantation
- Peptidase Inhibition and Analysis
- Chronic Myeloid Leukemia Treatments
- Cancer Mechanisms and Therapy
- Cancer therapeutics and mechanisms
- Synthesis and Biological Evaluation
- Polyomavirus and related diseases
- HIV/AIDS drug development and treatment
- Cancer Treatment and Pharmacology
- Acute Lymphoblastic Leukemia research
- T-cell and Retrovirus Studies
- Parvovirus B19 Infection Studies
- Economic and Financial Impacts of Cancer
- Cancer Genomics and Diagnostics
- Monoclonal and Polyclonal Antibodies Research
- CNS Lymphoma Diagnosis and Treatment
The University of Texas Southwestern Medical Center
2022-2025
Southwestern Medical Center
2022-2025
Harold C. Simmons Comprehensive Cancer Center
2023-2024
The University of Texas MD Anderson Cancer Center
2013-2022
Baylor College of Medicine
2019
Michael E. DeBakey VA Medical Center
2019
Saint Agnes Hospital
2016
Idecabtagene vicleucel (ide-cel) is an autologous B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy approved for relapsed/refractory multiple myeloma (RRMM) on the basis of phase II pivotal KarMMa trial, which demonstrated best overall and ≥ complete response rates 73% 33%, respectively. We report clinical outcomes with standard-of-care (SOC) ide-cel under commercial Food Drug Administration label.
Abstract Most patients with multiple myeloma experience disease relapse after treatment a B-cell maturation antigen-targeted therapy (BCMA-TT), and data describing outcomes for treated sequential BCMA-TT are limited. We analyzed clinical infused standard-of-care idecabtagene vicleucel, an anti-BCMA chimeric antigen receptor (CAR) T-cell therapy, at 11 US medical centers. A total of 50 prior exposure (38 antibody-drug conjugate, 7 bispecific, 5 CAR T) 153 no were ide-cel, median follow-up...
Abstract The overall survival (OS) has improved significantly in multiple myeloma (MM) over the last decade with use of proteasome inhibitor and immunomodulatory drug-based combinations, followed by high-dose melphalan autologous hematopoietic stem cell transplantation (auto-HSCT) subsequent maintenance therapies eligible newly diagnosed patients. However, clinical trials using auto-HSCT lenalidomide have shown an increased risk second primary malignancies (SPM), including hematological...
While response rates and survival outcomes have been very promising for idecabtagene vicleucel (ide-cel), a proportion of patients do not respond or relapse early after this B-cell maturation antigen (BCMA) targeted CAR T-cell therapy. Understanding the characteristics these is important patient selection development novel strategies to improve outcomes. We evaluated factors associated with progression (progression death due myeloma ≤ 3 months T infusion) in treated standard care ide-cel at...
PURPOSE Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), two B-cell maturation antigen–directed chimeric antigen receptor (CAR) T-cell therapies have demonstrated remarkable efficacy in relapsed/refractory multiple myeloma (RRMM). We compare safety, efficacy, survival among patients with RRMM treated standard-of-care (SOC) ide-cel or cilta-cel. METHODS Data were from a retrospective chart review of leukapheresed by December 31, 2022, the intent to receive SOC...
We evaluated patients with relapsed multiple myeloma renal impairment (RI) treated standard of care idecabtagene vicleucel (ide-cel), as outcomes chimeric antigen receptor (CAR) T-cell therapy are unknown in this population. RI was defined creatinine clearance (CrCl) <50 mL/min. CrCl <30 mL/min or dialysis dependence were severe RI. The study cohort included 214 patients, 28 (13%) RI, including 11 (dialysis, N=1). Patients older, more likely to be female and had higher likelihood...
<b><i>Background:</i></b> Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) are novel chimeric antigen receptor (CAR)-T cell therapies targeting B-cell maturation (BCMA), both have recently gained approval by the US Food Drug Administration (FDA) for treatment of relapsed refractory multiple myeloma (RRMM). <b><i>Summary:</i></b> These offer unprecedented responses in RRMM but present new challenges including cytokine...
Nephropathy due to BK virus (BKV) infection is an evolving challenge in patients undergoing hematopoietic stem cell transplantation (HSCT). We hypothesized that BKV was a marker of kidney function decline and poor prognostic factor HSCT recipients who experience this complication. In retrospective study, we analyzed all underwent their first allogeneic at our institution between 2004 2012. evaluated the incidence persistent decline, which defined as confirmed reduction estimated glomerular...
Central nervous system (CNS) relapse after allogeneic hematopoietic stem cell transplantation (HSCT) confers a poor prognosis in adult patients with acute lymphoblastic leukemia (ALL). Preventing CNS HSCT remains therapeutic challenge, and criteria for post-HSCT prophylaxis have not been addressed. In 3-center retrospective analysis, we reviewed the data 457 ALL who received first or second complete remission (CR). All as part of their upfront therapy ALL, but post-transplantation practice...
Idecabtagene vicleucel (ide-cel) was the first chimeric antigen receptor T-cell therapy to gain US Food and Drug Administration approval for patients with relapsed/refractory multiple myeloma (RRMM). The clinical outcomes of standard care (SOC) ide-cel in racially ethnically diverse populations have been understudied. This study pooled data from 207 RRMM (28% racial ethnic minority groups) treated SOC across 11 institutions examine differences incidence toxicities adverse events, response...
Despite the widespread use of carfilzomib (K) in relapsed/refractory multiple myeloma (RRMM), there is no consensus on optimal K dose milligrams per square meter (mg/m2) or dosing schedule. We assessed three modern prescribing patterns RRMM using a large United States electronic health record-derived database. Our final cohort (n = 486) included 136 patients (28.0%) who received 56 mg/m2 once weekly (K56-1x), 86 (17.7%) twice (K56-2x), and 264 (54.3%) 70 (K70-1x). Between 2016 2023,...
Outcomes of bispecific antibodies in patients with renal impairment (RI) are not well-characterized given the exclusion these from clinical trials. Herein, we evaluated relapsed/refractory multiple myeloma and RI treated standard-of-care teclistamab. was defined as creatinine clearance (CrCl) &lt;40mL/min. CrCl &lt;30mL/min or dialysis dependence were severe RI. Of 384 included patients, 81 (21%) had RI, including 45 (18%) 18 (5%) on dialysis. Patients more likely to be older (median...